The effect of the COVID-19 pandemic on severe asthma care in Europe: Will care change for good?

Katrien Eger; Dora Paroczai; Alison Bacon; Florence Schleich; Svetlana Sergejeva; Arnaud Bourdin; Isabelle Vachier; Eleftherios Zervas; Konstantinos Katsoulis; Dimosthenis Papapetrou; Konstantinos Kostikas; Zsuzsanna Csoma; Enrico Heffler; Giorgio Walter Canonica; Ineta Grisle; Kristina Bieksiene; Jolita Palacionyte; Anneke Ten Brinke; Simone Hashimoto; Frank W. J. M. Smeenk; Gert-Jan Braunstahl; Simone van der Sar; Florin Mihălţan; Natalia Nenasheva; Marina Peredelskaya; Biljana Zvezdin; Ivan Čekerevac; Sanja Hromiš; Vojislav Ćupurdija; Zorica Lazic; Branislava Milenkovic; Sanja Dimic-Janjic; Valentyna Yasinska; Barbro Dahlén; Apostolos Bossios; Nikolaos Lazarinis; David Aronsson; Arne Egesten; Abul Kashem Mohammad Munir; Lars Ahlbeck; Christer Janson; Sabina Škrgat; Natalija Edelbaher; Joerg Leuppi; Fabienne Jaun; Jochen Rüdiger; Nikolay Pavlov; Pietro Gianella; Reta Fischer; Florian Charbonnier; Rekha Chaudhuri; Steven James Smith; Simon Doe; Michelle Fawdon; Matthew Masoli; Liam Heaney; Hans Michael Haitchi; Ramesh Kurukulaaratchy; Olivia Fulton; Betty Frankemölle; Toni Gibson; Karen Needham; Peter Howarth; Ratko Djukanovic; Elisabeth Bel; Michael Hyland

doi:https://doi.org/10.1183/23120541.00065-2022

The effect of the COVID-19 pandemic on severe asthma care in Europe: Will care change for good?

Katrien Eger, Dora Paroczai, Alison Bacon, Florence Schleich, Svetlana Sergejeva, Arnaud Bourdin, Isabelle Vachier, Eleftherios Zervas, Konstantinos Katsoulis, Dimosthenis Papapetrou, Konstantinos Kostikas, Zsuzsanna Csoma, Enrico Heffler, Giorgio Walter Canonica, Ineta Grisle, Kristina Bieksiene, Jolita Palacionyte, Anneke Ten Brinke, Simone Hashimoto, Frank W. J. M. SmeenkGert-Jan Braunstahl, Simone van der Sar, Florin Mihălţan, Natalia Nenasheva, Marina Peredelskaya, Biljana Zvezdin, Ivan Čekerevac, Sanja Hromiš, Vojislav Ćupurdija, Zorica Lazic, Branislava Milenkovic, Sanja Dimic-Janjic, Valentyna Yasinska, Barbro Dahlén, Apostolos Bossios, Nikolaos Lazarinis, David Aronsson, Arne Egesten, Abul Kashem Mohammad Munir, Lars Ahlbeck, Christer Janson, Sabina Škrgat, Natalija Edelbaher, Joerg Leuppi, Fabienne Jaun, Jochen Rüdiger, Nikolay Pavlov, Pietro Gianella, Reta Fischer, Florian Charbonnier, Rekha Chaudhuri, Steven James Smith, Simon Doe, Michelle Fawdon, Matthew Masoli, Liam Heaney, Hans Michael Haitchi, Ramesh Kurukulaaratchy, Olivia Fulton, Betty Frankemölle, Toni Gibson, Karen Needham, Peter Howarth, Ratko Djukanovic, Elisabeth Bel, Michael Hyland

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

Background The coronavirus disease 2019 (COVID-19) pandemic has put pressure on healthcare services, forcing the reorganisation of traditional care pathways. We investigated how physicians taking care of severe asthma patients in Europe reorganised care, and how these changes affected patient satisfaction, asthma control and future care. Methods In this European-wide cross-sectional study, patient surveys were sent to patients with a physician-diagnosis of severe asthma, and physician surveys to severe asthma specialists between November 2020 and May 2021. Results 1101 patients and 268 physicians from 16 European countries contributed to the study. Common physician-reported changes in severe asthma care included use of video/phone consultations (46%), reduced availability of physicians (43%) and change to home-administered biologics (38%). Change to phone/video consultations was reported in 45% of patients, of whom 79% were satisfied or very satisfied with this change. Of 709 patients on biologics, 24% experienced changes in biologic care, of whom 92% were changed to home-administered biologics and of these 62% were satisfied or very satisfied with this change. Only 2% reported worsening asthma symptoms associated with changes in biologic care. Many physicians expect continued implementation of video/phone consultations (41%) and home administration of biologics (52%). Conclusions Change to video/phone consultations and home administration of biologics was common in severe asthma care during the COVID-19 pandemic and was associated with high satisfaction levels in most but not all cases. Many physicians expect these changes to continue in future severe asthma care, though satisfaction levels may change after the pandemic.

Original language	English
Article number	00065-2022
Journal	ERJ open research
Volume	8
Issue number	2
DOIs	https://doi.org/10.1183/23120541.00065-2022
Publication status	Published - 1 Apr 2022

Access to Document

https://doi.org/10.1183/23120541.00065-2022

Cite this

Eger, K., Paroczai, D., Bacon, A., Schleich, F., Sergejeva, S., Bourdin, A., Vachier, I., Zervas, E., Katsoulis, K., Papapetrou, D., Kostikas, K., Csoma, Z., Heffler, E., Canonica, G. W., Grisle, I., Bieksiene, K., Palacionyte, J., Brinke, A. T., Hashimoto, S., ... Hyland, M. (2022). The effect of the COVID-19 pandemic on severe asthma care in Europe: Will care change for good? ERJ open research, 8(2), [00065-2022]. https://doi.org/10.1183/23120541.00065-2022

@article{d0e190c1d4214399b672a04f47c453f0,

title = "The effect of the COVID-19 pandemic on severe asthma care in Europe: Will care change for good?",

abstract = "Background The coronavirus disease 2019 (COVID-19) pandemic has put pressure on healthcare services, forcing the reorganisation of traditional care pathways. We investigated how physicians taking care of severe asthma patients in Europe reorganised care, and how these changes affected patient satisfaction, asthma control and future care. Methods In this European-wide cross-sectional study, patient surveys were sent to patients with a physician-diagnosis of severe asthma, and physician surveys to severe asthma specialists between November 2020 and May 2021. Results 1101 patients and 268 physicians from 16 European countries contributed to the study. Common physician-reported changes in severe asthma care included use of video/phone consultations (46%), reduced availability of physicians (43%) and change to home-administered biologics (38%). Change to phone/video consultations was reported in 45% of patients, of whom 79% were satisfied or very satisfied with this change. Of 709 patients on biologics, 24% experienced changes in biologic care, of whom 92% were changed to home-administered biologics and of these 62% were satisfied or very satisfied with this change. Only 2% reported worsening asthma symptoms associated with changes in biologic care. Many physicians expect continued implementation of video/phone consultations (41%) and home administration of biologics (52%). Conclusions Change to video/phone consultations and home administration of biologics was common in severe asthma care during the COVID-19 pandemic and was associated with high satisfaction levels in most but not all cases. Many physicians expect these changes to continue in future severe asthma care, though satisfaction levels may change after the pandemic.",

author = "Katrien Eger and Dora Paroczai and Alison Bacon and Florence Schleich and Svetlana Sergejeva and Arnaud Bourdin and Isabelle Vachier and Eleftherios Zervas and Konstantinos Katsoulis and Dimosthenis Papapetrou and Konstantinos Kostikas and Zsuzsanna Csoma and Enrico Heffler and Canonica, {Giorgio Walter} and Ineta Grisle and Kristina Bieksiene and Jolita Palacionyte and Brinke, {Anneke Ten} and Simone Hashimoto and Smeenk, {Frank W. J. M.} and Gert-Jan Braunstahl and {van der Sar}, Simone and Florin Mih{\u a}l{\c t}an and Natalia Nenasheva and Marina Peredelskaya and Biljana Zvezdin and Ivan {\v C}ekerevac and Sanja Hromi{\v s} and Vojislav {\'C}upurdija and Zorica Lazic and Branislava Milenkovic and Sanja Dimic-Janjic and Valentyna Yasinska and Barbro Dahl{\'e}n and Apostolos Bossios and Nikolaos Lazarinis and David Aronsson and Arne Egesten and Munir, {Abul Kashem Mohammad} and Lars Ahlbeck and Christer Janson and Sabina {\v S}krgat and Natalija Edelbaher and Joerg Leuppi and Fabienne Jaun and Jochen R{\"u}diger and Nikolay Pavlov and Pietro Gianella and Reta Fischer and Florian Charbonnier and Rekha Chaudhuri and Smith, {Steven James} and Simon Doe and Michelle Fawdon and Matthew Masoli and Liam Heaney and Haitchi, {Hans Michael} and Ramesh Kurukulaaratchy and Olivia Fulton and Betty Frankem{\"o}lle and Toni Gibson and Karen Needham and Peter Howarth and Ratko Djukanovic and Elisabeth Bel and Michael Hyland",

note = "Funding Information: Acknowledgements: The SHARP CRC would like to acknowledge the support and expertise of the following individuals and groups without whom the study would not have been possible: Courtney Coleman (European Lung Foundation (ELF), Sheffield, UK), Emmanuelle Berret (European Respiratory Society, Lausanne, Switzerland), Elpiniki Papageorgiou-Georgatou (Medical Group of Athens, Athens, Greece), Petra Hirmann (Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands), Ekaterina Terekhova, Oksana Sebekina (both Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia), Violeta Kolarov (Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia), Agnes Csuth, Mohanad Abbas (both Allergy Center, Link{\"o}ping, Sweden) and Jacqueline Otker (ELF Patient Advisory Group). Funding Information: Support statement: The SHARP CRC has been supported by financial and other contributions from the following consortium partners: European Respiratory Society, GlaxoSmithKline Research and Development Limited, Chiesi Farmaceutici SPA, Novartis Pharma AG, Sanofi-Genzyme Corporation and Teva Branded Pharmaceutical Products R&D, Inc. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: Conflict of interest: A. Bourdin reports receiving grants or contracts outside the submitted work from AstraZeneca and Boeringher Ingelheim; and payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events as well as support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Chiesi and Amgen, outside the submitted work. Z. Csoma reports receiving honoraria for presentations from Astra/Zeneca, TEVA and Sanofi/Aventis (Hungary) outside the submitted work. E. Heffler reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from AstraZeneca, Sanofi-Genzyme, Regeneron, Novartis, GSK, Circassia; Stallergenes-Greer and Nestl{\`e} Purina outside the submitted work. G.W. Canonica reports receiving consulting fees from AstraZeneca GSK, Novartis, Sanofi and Stallergenes Greer; payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from AstraZeneca, GSK, Novartis, Sanofi, Stallergenes Greer, Menarini, Chiesi and Mylan; participation on data safety monitoring or advisory boards for AstraZeneca, GSK, Novartis, Sanofi, Stallergenes Greer and Chiesi; all disclosures made outside the submitted work. G-J. Braunstahl reports grants or contracts from GSK, AstraZeneca and ALK Abello; consulting fees from GSK, Sanofi, ALK Abello, AstraZeneca and Novartis; payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from GSK, Sanofi, ALK Abello, AstraZeneca and Novartis; and is on the scientific board of the Dutch Lung Foundation, task force Asthma NVALT and editorial board NTVAAKI; all disclosures made outside the submitted work. S. van der Sar reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from AstraZeneca and GSK; and support received from ALK for attending meetings and/or travel; all disclosures made outside the submitted work. N. Nenasheva reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from AstraZeneca plc., Sanofi S.A., Teva Pharmaceuticals, Novartis International AG and Chiesi Farmaceutici S.p.A., outside the submitted work. A. Bossios reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from AZ, GSK and Teva; support for attending meetings and/or travel received from Novartis; and participation on a data safety monitoring or advisory boards for AZ, GSK, Novartis, Teva and Sanofi; and is a member of the steering Committee of SHARP, Secretary of Assembly 5 (Airway diseases, asthma, COPD and chronic cough) of the European Respiratory Society and vice-chair of Nordic Severe Asthma Network; all disclosures made outside the submitted work. D. Aronsson reports receiving grants or contracts from ALK-Abello outside the submitted work. A. Egesten reports receiving honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from AstraZeneca, outside the submitted work. L. Ahlbeck reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from AstraZeneca; and participation on data safety monitoring or advisory boards for AstraZeneca, Sanofi and GSK; all disclosures made outside the submitted work. S. {\v S}krgat reports receiving honoraria for lectures and educational events supported by GSK, AstraZeneca, Sanofi, Chiesi, Pliva Teva and Medis; and participation on advisory boards of GSK, AstraZeneca, Chiesi and Sanofi; all disclosures made outside the submitted work. N. Edelbaher reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from GSK, Astra Zeneca, Chiesi, Pliva Teva, Krka, Novartis, Boehringer Ingelheim and Sanofi; and participation on advisory boards of GSK, Astra Zeneca, Chiesi, Novartis and Boehringer Ingelheim; all disclosures made outside the submitted work. J. R{\"u}diger reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from the Education of Swiss Emergency physicians; and participation on a data safety monitoring board or board for Boehringer Ingelheim; and is a member of the Board of the Swiss Society of Pneumology and President of the Thorax section of the Swiss Ultrasound Society; all disclosures made outside the submitted work. N. Pavlov reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from GSK, Novartis and OM Pharma; support for attending meetings and/or travel received from Boehringer Ingelheim; participation on data safety monitoring or advisory boards for AstraZeneca, GSK, Novartis and Sanofi; all disclosures made outside the submitted work. P. Gianella reports participation on an advisory board for Novartis about Xolair for nasal polyps, outside the submitted work. F. Charbonnier reports receiving payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from Sanofi, Novartis, Mundipharma, AstraZeneca and GSK; participation on data safety monitoring or advisory boards for Sanofi, Novartis, Mundipharma, AstraZeneca and GSK; all disclosures made outside the submitted work. R. Chaudhuri reports receiving grants or contracts from AstraZeneca; payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events from GSK, AstraZeneca, Teva, Chiesi, Sanofi and Novartis; support for attending meetings and/ or travel received from Chiesi, Napp, Sanofi, Boehringer, GSK and AZ; and participation on data safety monitoring or advisory boards for GSK, AstraZeneca, Teva, Chiesi and Novartis; all disclosures made outside the submitted work. S.J. Smith is supported by the Innovative Medicines Initiative 2 Joint Undertaking ( JU) under grant agreement number 831434 for Taxonomy, Targets, Treatment, and Remission; the JU receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associates; all disclosures made outside the submitted work. S. Doe reports receiving support for attending meetings and/or travel from GSK and Sanofi, outside the submitted work. L. Heaney reports grants or contracts from Medimmune, Novartis UK, Roche/Genentech Inc., GlaxoSmithKline, Amgen, Genentech/Hoffman la Roche, AstraZeneca, Medimmune, Aerocrine and Vitalograph; payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events for Novartis, Hoffman la Roche/Genentech Inc., Sanofi, GlaxoSmithKline, AstraZeneca, Teva and Circassia; support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; participation on data safety monitoring or advisory board for Novartis, Hoffman la Roche/Genentech Inc., Sanofi, Evelo Biosciences, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia; all disclosures made outside the submitted work. M. Masoli reports receiving grants or contracts from ERS SHARP to support the study “The burden of severe asthma on HRQoL across Europe”, outside the submitted work. P. Howarth is an employee of GSK. R. Djukanovic reports support for the present manuscript received from ERS, TEVA, GSK, Novartis, Sanofi and Chiesi; consulting fees from Synairgen for which the author is a co-founder and consultant and owns shares, outside the submitted work; and participation on a data safety monitoring or advisory board for Kymab (Cambridge), outside the submitted work. E. Bel reports support for the present manuscript from the ERS; grants or contracts received from GlaxoSmithKline and Teva, outside the submitted work; consulting fees received from AstraZeneca, GlaxoSmithKline, Sanofi, Sterna and Chiesi, outside the submitted work; honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events received from Teva; participation on a data safety monitoring or advisory board for AstraZeneca, outside the submitted work; and leadership or fiduciary roles, unpaid, for SHARP-CRC and RAPSODI (Dutch registry), outside the submitted work. M. Hyland reports receiving grants or contracts from TEVA; and payment or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing or educational events for GSK; all disclosures made outside the submitted work. The remaining authors have nothing to disclose. Publisher Copyright: {\textcopyright} The authors 2022.",

year = "2022",

month = apr,

day = "1",

doi = "https://doi.org/10.1183/23120541.00065-2022",

language = "English",

volume = "8",

journal = "BMJ open",

issn = "2044-6055",

publisher = "European Respiratory Society",

number = "2",

}

Eger, K, Paroczai, D, Bacon, A, Schleich, F, Sergejeva, S, Bourdin, A, Vachier, I, Zervas, E, Katsoulis, K, Papapetrou, D, Kostikas, K, Csoma, Z, Heffler, E, Canonica, GW, Grisle, I, Bieksiene, K, Palacionyte, J, Brinke, AT, Hashimoto, S, Smeenk, FWJM, Braunstahl, G-J, van der Sar, S, Mihălţan, F, Nenasheva, N, Peredelskaya, M, Zvezdin, B, Čekerevac, I, Hromiš, S, Ćupurdija, V, Lazic, Z, Milenkovic, B, Dimic-Janjic, S, Yasinska, V, Dahlén, B, Bossios, A, Lazarinis, N, Aronsson, D, Egesten, A, Munir, AKM, Ahlbeck, L, Janson, C, Škrgat, S, Edelbaher, N, Leuppi, J, Jaun, F, Rüdiger, J, Pavlov, N, Gianella, P, Fischer, R, Charbonnier, F, Chaudhuri, R, Smith, SJ, Doe, S, Fawdon, M, Masoli, M, Heaney, L, Haitchi, HM, Kurukulaaratchy, R, Fulton, O, Frankemölle, B, Gibson, T, Needham, K, Howarth, P, Djukanovic, R, Bel, E & Hyland, M 2022, 'The effect of the COVID-19 pandemic on severe asthma care in Europe: Will care change for good?', ERJ open research, vol. 8, no. 2, 00065-2022. https://doi.org/10.1183/23120541.00065-2022

TY - JOUR

T1 - The effect of the COVID-19 pandemic on severe asthma care in Europe

T2 - Will care change for good?

AU - Eger, Katrien

AU - Paroczai, Dora

AU - Bacon, Alison

AU - Schleich, Florence

AU - Sergejeva, Svetlana

AU - Bourdin, Arnaud

AU - Vachier, Isabelle

AU - Zervas, Eleftherios

AU - Katsoulis, Konstantinos

AU - Papapetrou, Dimosthenis

AU - Kostikas, Konstantinos

AU - Csoma, Zsuzsanna

AU - Heffler, Enrico

AU - Canonica, Giorgio Walter

AU - Grisle, Ineta

AU - Bieksiene, Kristina

AU - Palacionyte, Jolita

AU - Brinke, Anneke Ten

AU - Hashimoto, Simone

AU - Smeenk, Frank W. J. M.

AU - Braunstahl, Gert-Jan

AU - van der Sar, Simone

AU - Mihălţan, Florin

AU - Nenasheva, Natalia

AU - Peredelskaya, Marina

AU - Zvezdin, Biljana

AU - Čekerevac, Ivan

AU - Hromiš, Sanja

AU - Ćupurdija, Vojislav

AU - Lazic, Zorica

AU - Milenkovic, Branislava

AU - Dimic-Janjic, Sanja

AU - Yasinska, Valentyna

AU - Dahlén, Barbro

AU - Bossios, Apostolos

AU - Lazarinis, Nikolaos

AU - Aronsson, David

AU - Egesten, Arne

AU - Munir, Abul Kashem Mohammad

AU - Ahlbeck, Lars

AU - Janson, Christer

AU - Škrgat, Sabina

AU - Edelbaher, Natalija

AU - Leuppi, Joerg

AU - Jaun, Fabienne

AU - Rüdiger, Jochen

AU - Pavlov, Nikolay

AU - Gianella, Pietro

AU - Fischer, Reta

AU - Charbonnier, Florian

AU - Chaudhuri, Rekha

AU - Smith, Steven James

AU - Doe, Simon

AU - Fawdon, Michelle

AU - Masoli, Matthew

AU - Heaney, Liam

AU - Haitchi, Hans Michael

AU - Kurukulaaratchy, Ramesh

AU - Fulton, Olivia

AU - Frankemölle, Betty

AU - Gibson, Toni

AU - Needham, Karen

AU - Howarth, Peter

AU - Djukanovic, Ratko

AU - Bel, Elisabeth

AU - Hyland, Michael

N1 - Funding Information: Acknowledgements: The SHARP CRC would like to acknowledge the support and expertise of the following individuals and groups without whom the study would not have been possible: Courtney Coleman (European Lung Foundation (ELF), Sheffield, UK), Emmanuelle Berret (European Respiratory Society, Lausanne, Switzerland), Elpiniki Papageorgiou-Georgatou (Medical Group of Athens, Athens, Greece), Petra Hirmann (Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands), Ekaterina Terekhova, Oksana Sebekina (both Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia), Violeta Kolarov (Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia), Agnes Csuth, Mohanad Abbas (both Allergy Center, Linköping, Sweden) and Jacqueline Otker (ELF Patient Advisory Group). Funding Information: Support statement: The SHARP CRC has been supported by financial and other contributions from the following consortium partners: European Respiratory Society, GlaxoSmithKline Research and Development Limited, Chiesi Farmaceutici SPA, Novartis Pharma AG, Sanofi-Genzyme Corporation and Teva Branded Pharmaceutical Products R&D, Inc. Funding information for this article has been deposited with the Crossref Funder Registry. Funding Information: Conflict of interest: A. Bourdin reports receiving grants or contracts outside the submitted work from AstraZeneca and Boeringher Ingelheim; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events as well as support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Chiesi and Amgen, outside the submitted work. Z. Csoma reports receiving honoraria for presentations from Astra/Zeneca, TEVA and Sanofi/Aventis (Hungary) outside the submitted work. E. Heffler reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, Sanofi-Genzyme, Regeneron, Novartis, GSK, Circassia; Stallergenes-Greer and Nestlè Purina outside the submitted work. G.W. Canonica reports receiving consulting fees from AstraZeneca GSK, Novartis, Sanofi and Stallergenes Greer; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, GSK, Novartis, Sanofi, Stallergenes Greer, Menarini, Chiesi and Mylan; participation on data safety monitoring or advisory boards for AstraZeneca, GSK, Novartis, Sanofi, Stallergenes Greer and Chiesi; all disclosures made outside the submitted work. G-J. Braunstahl reports grants or contracts from GSK, AstraZeneca and ALK Abello; consulting fees from GSK, Sanofi, ALK Abello, AstraZeneca and Novartis; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, Sanofi, ALK Abello, AstraZeneca and Novartis; and is on the scientific board of the Dutch Lung Foundation, task force Asthma NVALT and editorial board NTVAAKI; all disclosures made outside the submitted work. S. van der Sar reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca and GSK; and support received from ALK for attending meetings and/or travel; all disclosures made outside the submitted work. N. Nenasheva reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca plc., Sanofi S.A., Teva Pharmaceuticals, Novartis International AG and Chiesi Farmaceutici S.p.A., outside the submitted work. A. Bossios reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AZ, GSK and Teva; support for attending meetings and/or travel received from Novartis; and participation on a data safety monitoring or advisory boards for AZ, GSK, Novartis, Teva and Sanofi; and is a member of the steering Committee of SHARP, Secretary of Assembly 5 (Airway diseases, asthma, COPD and chronic cough) of the European Respiratory Society and vice-chair of Nordic Severe Asthma Network; all disclosures made outside the submitted work. D. Aronsson reports receiving grants or contracts from ALK-Abello outside the submitted work. A. Egesten reports receiving honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca, outside the submitted work. L. Ahlbeck reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from AstraZeneca; and participation on data safety monitoring or advisory boards for AstraZeneca, Sanofi and GSK; all disclosures made outside the submitted work. S. Škrgat reports receiving honoraria for lectures and educational events supported by GSK, AstraZeneca, Sanofi, Chiesi, Pliva Teva and Medis; and participation on advisory boards of GSK, AstraZeneca, Chiesi and Sanofi; all disclosures made outside the submitted work. N. Edelbaher reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, Astra Zeneca, Chiesi, Pliva Teva, Krka, Novartis, Boehringer Ingelheim and Sanofi; and participation on advisory boards of GSK, Astra Zeneca, Chiesi, Novartis and Boehringer Ingelheim; all disclosures made outside the submitted work. J. Rüdiger reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from the Education of Swiss Emergency physicians; and participation on a data safety monitoring board or board for Boehringer Ingelheim; and is a member of the Board of the Swiss Society of Pneumology and President of the Thorax section of the Swiss Ultrasound Society; all disclosures made outside the submitted work. N. Pavlov reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, Novartis and OM Pharma; support for attending meetings and/or travel received from Boehringer Ingelheim; participation on data safety monitoring or advisory boards for AstraZeneca, GSK, Novartis and Sanofi; all disclosures made outside the submitted work. P. Gianella reports participation on an advisory board for Novartis about Xolair for nasal polyps, outside the submitted work. F. Charbonnier reports receiving payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Sanofi, Novartis, Mundipharma, AstraZeneca and GSK; participation on data safety monitoring or advisory boards for Sanofi, Novartis, Mundipharma, AstraZeneca and GSK; all disclosures made outside the submitted work. R. Chaudhuri reports receiving grants or contracts from AstraZeneca; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from GSK, AstraZeneca, Teva, Chiesi, Sanofi and Novartis; support for attending meetings and/ or travel received from Chiesi, Napp, Sanofi, Boehringer, GSK and AZ; and participation on data safety monitoring or advisory boards for GSK, AstraZeneca, Teva, Chiesi and Novartis; all disclosures made outside the submitted work. S.J. Smith is supported by the Innovative Medicines Initiative 2 Joint Undertaking ( JU) under grant agreement number 831434 for Taxonomy, Targets, Treatment, and Remission; the JU receives support from the European Union’s Horizon 2020 research and innovation programme, and the European Federation of Pharmaceutical Industries and Associates; all disclosures made outside the submitted work. S. Doe reports receiving support for attending meetings and/or travel from GSK and Sanofi, outside the submitted work. L. Heaney reports grants or contracts from Medimmune, Novartis UK, Roche/Genentech Inc., GlaxoSmithKline, Amgen, Genentech/Hoffman la Roche, AstraZeneca, Medimmune, Aerocrine and Vitalograph; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events for Novartis, Hoffman la Roche/Genentech Inc., Sanofi, GlaxoSmithKline, AstraZeneca, Teva and Circassia; support for attending meetings and/or travel from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Napp Pharmaceuticals; participation on data safety monitoring or advisory board for Novartis, Hoffman la Roche/Genentech Inc., Sanofi, Evelo Biosciences, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia; all disclosures made outside the submitted work. M. Masoli reports receiving grants or contracts from ERS SHARP to support the study “The burden of severe asthma on HRQoL across Europe”, outside the submitted work. P. Howarth is an employee of GSK. R. Djukanovic reports support for the present manuscript received from ERS, TEVA, GSK, Novartis, Sanofi and Chiesi; consulting fees from Synairgen for which the author is a co-founder and consultant and owns shares, outside the submitted work; and participation on a data safety monitoring or advisory board for Kymab (Cambridge), outside the submitted work. E. Bel reports support for the present manuscript from the ERS; grants or contracts received from GlaxoSmithKline and Teva, outside the submitted work; consulting fees received from AstraZeneca, GlaxoSmithKline, Sanofi, Sterna and Chiesi, outside the submitted work; honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Teva; participation on a data safety monitoring or advisory board for AstraZeneca, outside the submitted work; and leadership or fiduciary roles, unpaid, for SHARP-CRC and RAPSODI (Dutch registry), outside the submitted work. M. Hyland reports receiving grants or contracts from TEVA; and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events for GSK; all disclosures made outside the submitted work. The remaining authors have nothing to disclose. Publisher Copyright: © The authors 2022.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Background The coronavirus disease 2019 (COVID-19) pandemic has put pressure on healthcare services, forcing the reorganisation of traditional care pathways. We investigated how physicians taking care of severe asthma patients in Europe reorganised care, and how these changes affected patient satisfaction, asthma control and future care. Methods In this European-wide cross-sectional study, patient surveys were sent to patients with a physician-diagnosis of severe asthma, and physician surveys to severe asthma specialists between November 2020 and May 2021. Results 1101 patients and 268 physicians from 16 European countries contributed to the study. Common physician-reported changes in severe asthma care included use of video/phone consultations (46%), reduced availability of physicians (43%) and change to home-administered biologics (38%). Change to phone/video consultations was reported in 45% of patients, of whom 79% were satisfied or very satisfied with this change. Of 709 patients on biologics, 24% experienced changes in biologic care, of whom 92% were changed to home-administered biologics and of these 62% were satisfied or very satisfied with this change. Only 2% reported worsening asthma symptoms associated with changes in biologic care. Many physicians expect continued implementation of video/phone consultations (41%) and home administration of biologics (52%). Conclusions Change to video/phone consultations and home administration of biologics was common in severe asthma care during the COVID-19 pandemic and was associated with high satisfaction levels in most but not all cases. Many physicians expect these changes to continue in future severe asthma care, though satisfaction levels may change after the pandemic.

AB - Background The coronavirus disease 2019 (COVID-19) pandemic has put pressure on healthcare services, forcing the reorganisation of traditional care pathways. We investigated how physicians taking care of severe asthma patients in Europe reorganised care, and how these changes affected patient satisfaction, asthma control and future care. Methods In this European-wide cross-sectional study, patient surveys were sent to patients with a physician-diagnosis of severe asthma, and physician surveys to severe asthma specialists between November 2020 and May 2021. Results 1101 patients and 268 physicians from 16 European countries contributed to the study. Common physician-reported changes in severe asthma care included use of video/phone consultations (46%), reduced availability of physicians (43%) and change to home-administered biologics (38%). Change to phone/video consultations was reported in 45% of patients, of whom 79% were satisfied or very satisfied with this change. Of 709 patients on biologics, 24% experienced changes in biologic care, of whom 92% were changed to home-administered biologics and of these 62% were satisfied or very satisfied with this change. Only 2% reported worsening asthma symptoms associated with changes in biologic care. Many physicians expect continued implementation of video/phone consultations (41%) and home administration of biologics (52%). Conclusions Change to video/phone consultations and home administration of biologics was common in severe asthma care during the COVID-19 pandemic and was associated with high satisfaction levels in most but not all cases. Many physicians expect these changes to continue in future severe asthma care, though satisfaction levels may change after the pandemic.

UR - http://www.scopus.com/inward/record.url?scp=85134082717&partnerID=8YFLogxK

U2 - https://doi.org/10.1183/23120541.00065-2022

DO - https://doi.org/10.1183/23120541.00065-2022

M3 - Article

C2 - 35582679

SN - 2044-6055

VL - 8

JO - BMJ open

JF - BMJ open

IS - 2

M1 - 00065-2022

ER -

The effect of the COVID-19 pandemic on severe asthma care in Europe: Will care change for good?

Abstract

Access to Document

Other files and links

Cite this